Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer

Chen-Yu Huang, Min Cheng, Na-Rong Lee, Hsin-Yi Huang, Wen-Ling Lee, Wen-Hsun Chang, Peng-Hui Wang, Chen-Yu Huang, Min Cheng, Na-Rong Lee, Hsin-Yi Huang, Wen-Ling Lee, Wen-Hsun Chang, Peng-Hui Wang

Abstract

The use of weekly chemotherapy for the treatment of patients with advanced-stage serous-type epithelial Tubo-ovarian cancer (ETOC), and primary peritoneal serous carcinoma (PPSC) is acceptable as the front-line postoperative chemotherapy after primary cytoreductive surgery (PCS). The main component of dose-dense chemotherapy is weekly paclitaxel (80 mg/m2), but it would be interesting to know what is the difference between combination of triweekly cisplatin (20 mg/m2) or triweekly carboplatin (carboplatin area under the curve 5-7 mg/mL per min [AUC 5-7]) in the dose-dense paclitaxel regimen. Therefore, we compared the outcomes of women with Gynecology and Obstetrics (FIGO) stage IIIC ETOC and PPSC treated with PCS and a subsequent combination of dose-dense weekly paclitaxel and triweekly cisplatin (paclitaxel-cisplatin) or triweekly carboplatin using AUC 5 (paclitaxel-carboplatin). Between January 2010 and December 2016, 40 women with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC EOC, FTC, or PPSC were enrolled, including 18 treated with paclitaxel-cisplatin and the remaining 22 treated with paclitaxel-carboplatin. There were no statistically significant differences in disease characteristics of patients between two groups. Outcomes in paclitaxel-cisplatin group seemed to be little better than those in paclitaxel-carboplatin (median progression-free survival [PFS] 30 versus 25 months as well as median overall survival [OS] 58.5 versus 55.0 months); however, neither reached a statistically significant difference. In terms of adverse events (AEs), patients in paclitaxel-carboplatin group had more AEs, with a higher risk of neutropenia and grade 3/4 neutropenia, and the need for a longer period to complete the front-line chemotherapy, and the latter was associated with worse outcome for patients. We found that a period between the first-time chemotherapy to the last dose (6 cycles) of chemotherapy >21 weeks was associated with a worse prognosis in patients compared to that ≤21 weeks, with hazard ratio (HR) of 81.24 for PFS and 9.57 for OS. As predicted, suboptimal debulking surgery (>1 cm) also contributed to a worse outcome than optimal debulking surgery (≤1 cm) with HR of 14.38 for PFS and 11.83 for OS. Based on the aforementioned findings, both regimens were feasible and effective, but maximal efforts should be made to achieve optimal debulking surgery and following the on-schedule administration of dose-dense weekly paclitaxel plus triweekly platinum compounds. Randomized trials validating the findings are warranted.

Keywords: FIGO stage IIIC; dose-dense weekly paclitaxel; epithelial tubo-ovarian cancer; primary peritoneal serous carcinoma; triweekly carboplatin; triweekly cisplatin.

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Progression-free survival curves for patients treated either with carboplatin-based dose-dense chemotherapy or with cisplatin-based dose-dense chemotherapy.
Figure 2
Figure 2
Overall survival curves of patients for patients treated either with carboplatin-based dose-dense chemotherapy or with cisplatin-based dose-dense chemotherapy.

References

    1. Berek J.S., Kehoe S.T., Kumar L., Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet. 2018;143(Suppl. 2):59–78. doi: 10.1002/ijgo.12614.
    1. Torre L.A., Trabert B., DeSantis C.E., Miller K.D., Samimi G., Runowicz C.D., Gaudet M.M., Jemal A., Siegel R.L. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 2018;68:284–296. doi: 10.3322/caac.21456.
    1. Stenzel A.E., Buas M.F., Moysich K.B. Survival disparities among racial/ethnic groups of women with ovarian cancer: An update on data from the Surveillance, Epidemiology and End Results (SEER) registry. Cancer. Epidemiol. 2019;62:101580. doi: 10.1016/j.canep.2019.101580.
    1. Armstrong D.K., Alvarez R.D., Bakkum-Gamez J.N., Barroilhet L., Behbakht K., Berchuck A., Berek J.S., Chen L.M., Cristea M., DeRosa M., et al. NCCN guidelines insights: Ovarian cancer, version 1.2019. J. Natl. Compr. Cancer Netw. 2019;17:896–909. doi: 10.6004/jnccn.2019.0039.
    1. Hanchette C., Zhang C.H., Schwartz G.G. Ovarian cancer incidence in the U.S. and toxic emissions from pulp and paper plants: A geospatial analysis. Int. J. Environ. Res. Public Health. 2018;15:1619. doi: 10.3390/ijerph15081619.
    1. Chen S.N., Chang R., Lin L.T., Chern C.U., Tsai H.W., Wen Z.H., Li Y.H., Li C.J., Tsui K.H. MicroRNA in ovarian cancer: Biology, pathogenesis, and therapeutic opportunities. Int. J. Environ. Res. Public Health. 2019;16:1510. doi: 10.3390/ijerph16091510.
    1. Hsu H.C., Tseng K.Y., Wang H.C., Sung F.C., Ma W.F. Risk of endometriosis and subsequent ovary and breast cancers in nurses: A population-based cohort study in Taiwan. Int. J. Environ. Res. Public Health. 2019;16:3469. doi: 10.3390/ijerph16183469.
    1. Oda K., Hamanishi J., Matsuo K., Hasegawa K. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. Gynecol. Oncol. 2018;151:381–389. doi: 10.1016/j.ygyno.2018.09.001.
    1. Murakami K., Kotani Y., Shiro R., Takaya H., Nakai H., Matsumura N. Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts. Int. J. Clin. Oncol. 2020;25:51–58. doi: 10.1007/s10147-019-01536-5.
    1. Haraguchi H., Koga K., Takamura M., Makabe T., Sue F., Miyashita M., Urata Y., Izumi G., Harada M., Hirata T., et al. Development of ovarian cancer after excision of endometrioma. Fertil. Steril. 2016;106:1432–1437. doi: 10.1016/j.fertnstert.2016.07.1077.
    1. Su K.M., Wang P.H., Yu M.H., Chang C.M., Chang C.C. The recent progress and therapy in endometriosis-associated ovarian cancer. J. Chin. Med. Assoc. 2020;83:227–232. doi: 10.1097/JCMA.0000000000000262.
    1. Kim J., Park E.Y., Kim O., Schilder J.M., Coffey D.M., Cho C.H., Bast R.C., Jr. Cell origins of high-grade serous ovarian cancer. Cancers. 2018;10:433. doi: 10.3390/cancers10110433.
    1. Lisio M.A., Fu L., Goyeneche A., Gao Z.H., Telleria C. High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int. J. Mol. Sci. 2019;20:952. doi: 10.3390/ijms20040952.
    1. Nakamura M., Obata T., Daikoku T., Fujiwara H. The association and significance of p53 in gynecologic cancers: The potential of targeted therapy. Int. J. Mol. Sci. 2019;20:5482. doi: 10.3390/ijms20215482.
    1. Sun M., Bao L., Shen H., Ji M., Yao L., Yi X., Jiang W. Unexpected primary fallopian tube carcinoma during gynecological operations: Clinicopathological and prognostic factors analyses of 67 cases. Taiwan J. Obstet. Gynecol. 2019;58:626–632. doi: 10.1016/j.tjog.2019.07.008.
    1. Coan M., Rampioni Vinciguerra G.L., Cesaratto L., Gardenal E., Bianchet R., Dassi E., Vecchione A., Baldassarre G., Spizzo R., Nicoloso M.S. Exploring the role of Fallopian ciliated cells in the pathogenesis of high-grade serous ovarian cancer. Int. J. Mol. Sci. 2018;19:2512. doi: 10.3390/ijms19092512.
    1. Chang C.C., Su K.M., Lu K.H., Lin C.K., Wang P.H., Li H.Y., Wang M.L., Lin C.K., Yu M.H., Chang C.M. Key immunological functions involved in the progression of epithelial ovarian serous carcinoma discovered by the gene ontology-based immunofunctionome analysis. Int. J. Mol. Sci. 2018;19:3311. doi: 10.3390/ijms19113311.
    1. Sung P.L., Wen K.C., Chen Y.J., Chao T.C., Tsai Y.F., Tseng L.M., Qiu J.T., Chao K.C., Wu H.H., Chuang C.M., et al. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels. PLoS ONE. 2017;12:e0185615. doi: 10.1371/journal.pone.0185615.
    1. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996;334:1–6. doi: 10.1056/NEJM199601043340101.
    1. Piccart M.J., Bertelsen K., Stuart G., Cassidy J., Mangioni C., Simonsen E., James K., Kaye S., Vergote I., Blom R., et al. Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Int. J. Gynecol. Cancer. 2003;13:144–148.
    1. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., Stuart G., Kaye S., Vergote I., Blom R., et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J. Natl. Cancer Inst. 2000;92:699–708. doi: 10.1093/jnci/92.9.699.
    1. Alberts D.S. Carboplatin versus cisplatin in ovarian cancer. Semin. Oncol. 1995;22:88–90.
    1. Neijt J.P., Engelholm S.A., Tuxen M.K., Sorensen P.G., Hansen M., Sessa C., de Swart C.A., Hirsch F.R., Lund B., van Houwelingen H.C. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 2000;18:3084–3092. doi: 10.1200/JCO.2000.18.17.3084.
    1. du Bois A., Lück H.J., Meier W., Adams H.P., Mobus V., Costa S., Bauknecht T., Richter B., Warm M., Schröder W., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 2003;95:1320–1329. doi: 10.1093/jnci/djg036.
    1. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., Mannel R.S., DeGeest K., Hartenbach E.M., Baerge R., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J. Clin. Oncol. 2003;21:3194–3200. doi: 10.1200/JCO.2003.02.153.
    1. NCCN Clinical Practice Guideline in Oncology, Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 1.2020—March 11, 2020. [(accessed on 18 March 2020)]; Available online:
    1. Tewari K.S., Burger R.A., Enserro D., Norquist B.M., Swisher E.M., Brady M.F., Bookman M.A., Fleming G.F., Huang H., Homesley H.D., et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J. Clin. Oncol. 2019;37:2317–2328. doi: 10.1200/JCO.19.01009.
    1. Chelariu-Raicu A., Coleman R.L., Sood A.K. Anti-angiogenesis therapy in ovarian cancer: Which patient is it most likely to benefit? Oncology. 2019;33:629378.
    1. Oza A.M., Cook A.D., Pfisterer J., Embleton A., Ledermann J.A., Pujade-Lauraine E., Kristensen G., Carey M.S., Beale P., Cervantes A., et al. ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–936. doi: 10.1016/S1470-2045(15)00086-8.
    1. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., Carey M.S., Beale P., Cervantes A., Kurzeder C., et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011;365:2484–2496. doi: 10.1056/NEJMoa1103799.
    1. Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., Mannel R.S., Homesley H.D., Fowler J., Greer B.E., et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011;365:2473–2483. doi: 10.1056/NEJMoa1104390.
    1. Pignata S., Scambia G., Katsaros D., Gallo C., Pujade-Lauraine E., De Placido S., Bologna A., Weber B., Raspagliesi F., Panici P.B., et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014;15:396–405. doi: 10.1016/S1470-2045(14)70049-X.
    1. Clamp A.R., James E.C., McNeish I.A., Dean A., Kim J.W., O’Donnell D.M., Hook J., Coyle C., Blagden S., Brenton J.D., et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): Primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet. 2019;394:2084–2095. doi: 10.1016/S0140-6736(19)32259-7.
    1. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., Parkin D., Paul J., Hay A., Kaye S.B., et al. Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl. Cancer Inst. 2004;96:1682–1691. doi: 10.1093/jnci/djh323.
    1. Mori T., Hosokawa K., Kinoshita Y., Watanabe A., Yamaguchi T., Kuroboshi H., Kato Y., Yasuda J., Fujita H., Nakata Y., et al. A pilot study of docetaxel–carboplatin versus paclitaxel–carboplatin in Japanese patients with epithelial ovarian cancer. Int. J. Clin. Oncol. 2007;12:205–211. doi: 10.1007/s10147-007-0656-z.
    1. Pignata S., Scambia G., Ferrandina G., Savarese A., Sorio R., Breda E., Gebbia V., Musso P., Frigerio L., Del Medico P., et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. J. Clin. Oncol. 2011;29:3628–3635. doi: 10.1200/JCO.2010.33.8566.
    1. Bookman M.A., Brady M.F., McGuire W.P., Harper P.G., Alberts D.S., Friedlander M., Colombo N., Fowler J.M., Argenta P.A., De Geest K., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A Phase III Trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 2009;27:1419–1425. doi: 10.1200/JCO.2008.19.1684.
    1. Staropoli N., Ciliberto D., Botta C., Fiorillo L., Grimaldi A., Lama S., Caraglia M., Salvino A., Tassone P., Tagliaferri P. Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials. Cancer. Biol. Ther. 2014;15:707–720. doi: 10.4161/cbt.28557.
    1. Katsumata N., Yasuda M., Takahashi F., Isonishi S., Jobo T., Aoki D., Tsuda H., Sugiyama T., Kodama S., Kimura E., et al. Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331–1338. doi: 10.1016/S0140-6736(09)61157-0.
    1. Katsumata N., Yasuda M., Isonishi S., Takahashi F., Michimae H., Kimura E., Aoki D., Jobo T., Kodama S., Terauchi F., et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial. Lancet Oncol. 2013;14:1020–1026. doi: 10.1016/S1470-2045(13)70363-2.
    1. Chan J.K., Brady M.F., Penson R.T., Huang H., Birrer M.J., Walker J.L., DiSilvestro P.A., Rubin S.C., Martin L.P., Davidson S.A., et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N. Engl. J. Med. 2016;374:738–748. doi: 10.1056/NEJMoa1505067.
    1. Fujiwara K., Hasegawa K., Nagao S. Landscape of systemic therapy for ovarian cancer in 2019: Primary therapy. Cancer. 2019;125(Suppl. 24):4582–4586. doi: 10.1002/cncr.32475.
    1. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., Walker J.L., Burger R.A., Gynecologic Oncology Group Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006;354:34–43. doi: 10.1056/NEJMoa052985.
    1. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., Wadler S., Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 2001;19:1001–1007.
    1. Chandra A., Pius C., Nabeel M., Nair M., Vishwanatha J.K., Ahmad S., Basha R. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer Med. 2019;8:7018–7031. doi: 10.1002/cam4.2560.
    1. Lheureux S., Gourley C., Vergote I., Oza A.M. Epithelial ovarian cancer. Lancet. 2019;393:1240–1253. doi: 10.1016/S0140-6736(18)32552-2.
    1. Marchetti C., De Felice F., Di Pinto A., D’Oria O., Aleksa N., Musella A. Dose-dense weekly chemotherapy in advanced ovarian cancer: An updated meta-analysis of randomized controlled trials. Crit. Rev. Oncol. Hematol. 2018;125:30–34. doi: 10.1016/j.critrevonc.2018.02.016.
    1. Marth C., Reimer D., Zeimet A.G. Front-line therapy of advanced epithelial ovarian cancer: Standard treatment. Ann. Oncol. 2017;28:viii36–viii39. doi: 10.1093/annonc/mdx450.
    1. Kemp Z., Ledermann J. Update on first-line treatment of advanced ovarian carcinoma. Int. J. Womens Health. 2013;5:45–51.
    1. Bookman M.A. First-line chemotherapy in epithelial ovarian cancer. Clin. Obstet. Gynecol. 2012;55:96–113. doi: 10.1097/GRF.0b013e31824b45da.
    1. Su M.H., Chen G.Y., Lin J.H., Lee H.H., Chung K.C., Wang P.H. Paclitaxel-related dermatological problems: Not only alopecia occurs. Taiwan. J. Obstet. Gynecol. 2019;58:877–879. doi: 10.1016/j.tjog.2019.08.003.
    1. Liu C.H., Horng H.C., Wang P.H. A case of ovarian cancer present with acute respiratory distress: Spontaneous rupture of diaphragm. Taiwan J. Obstet. Gynecol. 2019;58:712–714. doi: 10.1016/j.tjog.2019.07.024.
    1. Su M.H., Cho S.W., Kung Y.S., Lin J.H., Lee W.L., Wang P.H. Update on the differential diagnosis of gynecologic organ-related diseases in women presenting with ascites. Taiwan J. Obstet. Gynecol. 2019;58:587–591. doi: 10.1016/j.tjog.2019.07.002.
    1. Hsieh S.F., Lau H.Y., Wu H.H., Hsu H.C., Twu N.F., Cheng W.F. Prognostic factors of early stage epithelial ovarian carcinoma. Int. J. Environ. Res. Public Health. 2019;16:637. doi: 10.3390/ijerph16040637.
    1. Chang H.T., Chiu M.L., Wang T.Y., Chen T.C., Chang C.L., Su T.H., Wang K.G., Wang K.L., Yang Y.C., Chen J.R. Effect of chemotherapy, laparoscopy, and cytology on stage IC ovarian clear cell carcinoma: A long-term, single-center study. Int. J. Environ. Res. Public Health. 2020;17:491. doi: 10.3390/ijerph17020491.
    1. Lee J.M., Minasian L., Kohn E.C. New strategies in ovarian cancer treatment. Cancer. 2019;125(Suppl. 24):4623–4629. doi: 10.1002/cncr.32544.
    1. Tsibulak I., Zeimet A.G., Marth C. Hopes and failures in front-line ovarian cancer therapy. Crit. Rev. Oncol. Hematol. 2019;143:14–19. doi: 10.1016/j.critrevonc.2019.08.002.
    1. Wendel Naumann R., Coleman R.L., Brown J., Moore K.N. Phase III trials in ovarian cancer: The evolving landscape of front line therapy. Gynecol. Oncol. 2019;153:436–444. doi: 10.1016/j.ygyno.2019.02.008.
    1. Liu J., Matulonis U.A. New advances in ovarian cancer. Oncology. (Williston Park) 2010;24:721–728.
    1. Markman M. Chemotherapy: Limited use of the intraperitoneal route for ovarian cancer-why? Nat. Rev. Clin. Oncol. 2015;12:628–630. doi: 10.1038/nrclinonc.2015.177.
    1. van der Burg M.E., van Lent M., Buyse M., Kobierska A., Colombo N., Favalli G., Lacave A.J., Nardi M., Renard J., Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N. Engl. J. Med. 1995;332:629–634. doi: 10.1056/NEJM199503093321002.
    1. Vergote I., Trope C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., Verheijen R.H., van der Burg M.E., Lacave A.J., Panici P.B., et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 2010;363:943–953. doi: 10.1056/NEJMoa0908806.
    1. Vergote I., Tropé C.G., Amant F., Ehlen T., Reed N.S., Casado A. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. J. Clin. Oncol. 2011;29:4076–4078. doi: 10.1200/JCO.2011.36.9785.
    1. Kusunoki S., Terao Y., Hirayama T., Fujino K., Ujihira T., Ota T., Takeda S. Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients. Taiwan J. Obstet. Gynecol. 2018;57:650–653. doi: 10.1016/j.tjog.2018.08.006.
    1. Wang P.H. Neoadjuvant chemotherapy before definite operative approach for women with advanced-stage epithelial ovarian cancer. Taiwan J. Obstet. Gynecol. 2018;57:623–624. doi: 10.1016/j.tjog.2018.08.001.
    1. Bartels H.C., Rogers A.C., McSharry V., McVey R., Walsh T., O’Brien D., Boyd W.D., Brennan D.J. A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy. Gynecol. Oncol. 2019;154:622–630. doi: 10.1016/j.ygyno.2019.07.011.
    1. Shibutani T., Nagao S., Suzuki K., Kaneda M., Yamamoto K., Jimi T., Yano H., Kitai M., Shiozaki T., Matsuoka K., et al. Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: A retrospective study. Int. J. Clin. Oncol. 2019 doi: 10.1007/s10147-019-01567-y.
    1. Kim Y.N., Lee Y.J., Lee J.Y., Nam E.J., Kim S.W., Kim S., Kim Y.T. Comparison between weekly versus 3-weekly paclitaxel in combination with carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer. J. Gynecol. Oncol. 2020;31:e23. doi: 10.3802/jgo.2020.31.e23.
    1. Coleridge S.L., Bryant A., Lyons T.J., Goodall R.J., Kehoe S., Morrison J. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane. Database. Syst. Rev. 2019;10:CD005343. doi: 10.1002/14651858.CD005343.pub4.
    1. Hasegawa K., Shimada M., Takeuchi S., Fujiwara H., Imai Y., Iwasa N., Wada S., Eguchi H., Oishi T., Sugiyama T., et al. A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer. Br. J. Cancer. 2020 doi: 10.1038/s41416-020-0734-9.
    1. Shi T., Jiang R., Pu H., Yang H., Tu D., Dai Z., Cai Y., Zhang Y., Cheng X., Jia H., et al. Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: A randomised controlled study. Br. J. Cancer. 2019;121:425–428. doi: 10.1038/s41416-019-0543-1.
    1. Walker J.L., Brady M.F., Wenzel L., Fleming G.F., Huang H.Q., DiSilvestro P.A., Fujiwara K., Alberts D.S., Zheng W., Tewari K.S., et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J. Clin. Oncol. 2019;37:1380–1390. doi: 10.1200/JCO.18.01568.
    1. Marchetti C., De Felice F., Perniola G., Palaia I., Musella A., Di Donato V., Cascialli G., Cascialli G., Muzii L., Tombolini V., et al. Role of intraperitoneal chemotherapy in ovarian cancer in the platimum-taxane-based era: A meta-analysis. Crit. Rev. Oncol. Hematol. 2019;136:64–69. doi: 10.1016/j.critrevonc.2019.01.002.
    1. van Driel W.J., Koole S.N., Sikorska K., Schagen van Leeuwen J.H., Schreuder H.W.R., Hermans R.H.M., Hermans R.H.M., de Hingh I.H.J.T., van der Velden J., Arts H.J., et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl. J. Med. 2018;378:230–240. doi: 10.1056/NEJMoa1708618.
    1. Auer R.C., Sivajohanathan D., Biagi J., Conner J., Kennedy E., May T. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: A systematic review. Eur. J. Cancer. 2020;127:76–95. doi: 10.1016/j.ejca.2019.10.034.
    1. du Bois A., Floquet A., Kim J.W., Rau J., del Campo J.M., Friedlander M., Pignata S., Fujiwara K., Vergote I., Colombo N., et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J. Clin. Oncol. 2014;32:3374–3382. doi: 10.1200/JCO.2014.55.7348.
    1. du Bois A., Kristensen G., Ray-Coquard I., Reuss A., Pignata S., Colombo N., Denison U., Vergote I., Del Campo J.M., Ottevanger P., et al. AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016;17:78–89.
    1. Coleman R.L., Oza A.M., Lorusso D., Aghajanian C., Oaknin A., Dean A., Colombo N., Weberpals J.I., Clamp A., Scambia G., et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949–1961. doi: 10.1016/S0140-6736(17)32440-6.
    1. Liu C.H., Chang Y., Wang P.H. Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer. Taiwan J. Obstet. Gynecol. 2017;56:713–714. doi: 10.1016/j.tjog.2017.08.026.
    1. Moore K., Colombo N., Scambia G., Kim B.G., Oaknin A., Friedlander M., Lisyanskaya A., Floquet A., Leary A., Sonke G.S., et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 2018;379:2495–2505. doi: 10.1056/NEJMoa1810858.
    1. Vergote I., du Bois A., Floquet A., Rau J., Kim J.W., Del Campo J.M., Friedlander M., Pignata S., Fujiwara K., Colombo N., et al. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol. Oncol. 2019;155:186–191. doi: 10.1016/j.ygyno.2019.08.024.
    1. Boussios S., Karihtala P., Moschetta M., Karathanasi A., Sadauskaite A., Rassy E., Pavlidis N. Combined strategies with poly (ADP-Ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: A literature review. Diagnostics. 2019;9:87. doi: 10.3390/diagnostics9030087.
    1. Feng Y., Huang H., Wan T., Zhang C., Tong C., Liu J. Comparison of PARPis with angiogenesis inhibitors and chemotherapy for maintenance in ovarian cancer: A network meta-analysis. Adv. Ther. 2019;36:3368–3380. doi: 10.1007/s12325-019-01106-1.
    1. Vergote I., Scambia G., O’Malley D.M., Van Calster B., Park S.Y., Del Campo J.M., Meier W., Bamias A., Colombo N., Wenham R.M., et al. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): A randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:862–876. doi: 10.1016/S1470-2045(19)30178-0.
    1. Coleman R.L., Fleming G.F., Brady M.F., Swisher E.M., Steffensen K.D., Friedlander M., Okamoto A., Moore K.N., Efrat Ben-Baruch N., Werner T.L., et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N. Engl. J. Med. 2019;381:2403–2415. doi: 10.1056/NEJMoa1909707.
    1. Beaver J.A., Coleman R.L., Arend R.C., Armstrong D.K., Bala S., Mills G.B., Sood A.K., Herzog T.J. Advancing drug development in gynecologic malignancies. Clin. Cancer Res. 2019;25:4874–4880. doi: 10.1158/1078-0432.CCR-19-0619.
    1. Lee W.L., Wang P.H. Aberrant sialylation in ovarian cancers. J. Chin. Med. Assoc. 2020;83:337–344. doi: 10.1097/JCMA.0000000000000252.
    1. Matanes E., Gotlieb W.H. Immunotherapy of gynecological cancers. Best Pract. Res. Clin. Obstet. Gynaecol. 2019;60:97–110. doi: 10.1016/j.bpobgyn.2019.03.005.
    1. Lee W.L., Wang P.H. Immunology and ovarian cancers. J. Chin. Med. Assoc. 2020;83:425–432. doi: 10.1097/JCMA.0000000000000283.
    1. Suidan R.S., He W., Sun C.C., Zhao H., Rauh-Hain J.A., Fleming N.D., Lu K.H., Giordano S.H., Meyer L.A. Total and out-of-pocket costs of different primary management strategies in ovarian cancer. Am. J. Obstet. Gynecol. 2019;221:136.e1–136.e9. doi: 10.1016/j.ajog.2019.04.005.
    1. Markman M., Liu P.Y., Wilczynski S., Monk B., Copeland L.J., Alvarez R.D., Jiang C., Alberts D., Southwest Oncology Group. Gynecologic Oncology Group Southwest Oncology, Oncology G. Gynecologic, Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J. Clin. Oncol. 2003;21:2460–2465.
    1. de Jongh F.E., de Wit R., Verweij J., Sparreboom A., van den Bent M.J., Stoter G., van der Burg M.E. Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur. J. Cancer. 2002;38:2005–2013. doi: 10.1016/S0959-8049(02)00242-3.
    1. Viret F., Bertucci F., Genre D., Gravis G., Chabannon C., Conte M., Houvenaeghel G., Maraninchi D., Viens P. Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: A phase II study. Bone, Marrow, Transplant. 2002;30:879–884. doi: 10.1038/sj.bmt.1703762.
    1. Marchetti P., Urien S., Cappellini G.A., Ronzino G., Ficorella C. Weekly administration of paclitaxel: Theoretical and clinical basis. Crit. Rev. Oncol. Hematol. 2002;44:S3–S13. doi: 10.1016/S1040-8428(02)00109-9.
    1. Fizazi K., Zelek L. Is one cycle every three or four week’s obsolete? A critical review of dose-dense chemotherapy in solid neoplasms. Ann. Oncol. 2000;11:133–149. doi: 10.1023/A:1008344014518.
    1. Goldie J.H., Coldman A.J. The genetic origin of drug resistance in neoplasms: Implication for systemic therapy. Cancer. Res. 1984;44:3643–3653.
    1. Norton L., Simon R. The Norton-Simon hypothesis revisited. Cancer. Treat. Rep. 1986;70:163–169.
    1. Simon R., Norton L. The Norton-Simon hypothesis: Designing more effective and less toxic chemotherapeutic regimens. Nat. Clin. Pract. Oncol. 2006;3:406–407. doi: 10.1038/ncponc0560.
    1. Sparano J.A., Wang M., Martino S., Jones V., Perez E.A., Saphner T., Wolff A.C., Sledge G.W., Jr., Wood W.C., Davidson N.E. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 2008;358:1663–1671. doi: 10.1056/NEJMoa0707056.
    1. Milani A., Kristeleit R., McCormack M., Raja F., Luvero D., Widschwendter M., MacDonald N., Mould T., Olatain A., Hackshaw A., et al. Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: A retrospective study of feasibility and efficacy. ESMO Open. 2017;1:e000117. doi: 10.1136/esmoopen-2016-000117.
    1. Rettenmaier M.A., Micha J.P., Bohart R., Goldstein B.H. A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 2020;44:101–105. doi: 10.1016/j.ejogrb.2019.10.047.
    1. Murphy M., Martin G., Mahmoudjafari Z., Bivona C., Grauer D., Henry D. Intraperitoneal paclitaxel and cisplatin compared with dose-dense paclitaxel and carboplatin for patients with stage III ovarian cancer. J. Oncol. Pharm. Pract. 2020:1078155219899460. doi: 10.1177/1078155219899460.
    1. Chang C.L., Hsu Y.T., Wu C.C., Lai Y.Z., Wang C., Yang Y.C., Wu T.C., Hung C.F. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer. Res. 2013;73:119–127. doi: 10.1158/0008-5472.CAN-12-2225.
    1. Stasenko M., Reynolds R.K., Johnston C., Brackman M., McLean K., Uppal S. Adherence to hematologic hold parameters in carboplatin and dose-dense paclitaxel chemotherapy for ovarian malignancies: A survey of NCCN member institutions. J. Natl. Compr. Cancer Netw. 2016;14:849–853. doi: 10.6004/jnccn.2016.0089.
    1. Boraska Jelavić T., Boban T., Brčić L., Vrdoljak E. Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel–carboplatin combination therapy in patients with epithelial ovarian cancer? Anticancer Drugs. 2017;28:922–927. doi: 10.1097/CAD.0000000000000538.
    1. Huang C.Y., Yang Y.C., Wang K.L., Chen T.C., Chen J.R., Weng C.S., Chien H.J., Chang C.L. Possible surrogate marker for an effective dose-dense chemotherapy in treating ovarian cancer. Taiwan J Obstet. Gynecol. 2016;55:405–409. doi: 10.1016/j.tjog.2016.04.017.
    1. Lee W.L., Chan I.S., Wang P.H. Does a simple hematological examination predict the response and side effects in patients undergoing induction chemotherapy and/or neoadjuvant chemotherapy? J. Chin. Med. Assoc. 2020;83:107–108. doi: 10.1097/JCMA.0000000000000239.
    1. Vasey P.A. “Dose dense” chemotherapy in ovarian cancer. Int. J. Gynecol. Cancer. 2005;15(Suppl. 3):226–232. doi: 10.1111/j.1525-1438.2005.00438.x.
    1. Muggia F.M. Sequential single agents as first-line chemotherapy for ovarian cancer: A strategy derived from the results of GOG-132. Int. J. Gynecol. Cancer. 2003;13(Suppl. 2):156–162. doi: 10.1136/ijgc-00009577-200311001-00005.
    1. Muggia F.M. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer. Semin. Oncol. 2004;31(Suppl. 15):19–24. doi: 10.1053/j.seminoncol.2004.11.024.
    1. van der Burg M.E., van der Gaast A., Vergote I., Burger C.W., van Doorn H.C., de Wit R., Stoter G., Verweij J. What is the role of dose-dense therapy? Int. J. Gynecol. Cancer. 2005;15(Suppl. 3):233–240. doi: 10.1111/j.1525-1438.2005.00432.x.
    1. van den Bent M.J., van Putten W.L., Hilkens P.H., de Wit R., van der Burg M.E. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. Eur. J. Cancer. 2002;38:387–391. doi: 10.1016/S0959-8049(01)00381-1.
    1. Vasey P.A., Kaye S.B. Dose intensity in ovarian cancer. In: Gershenson D.M., McGuire W.P., editors. Ovarian Cancer Controversies in Management. Churchill Livingstone; New York, NY, USA: 1997. pp. 139–169.
    1. Fruscio R., Garbi A., Parma G., Lissoni A.A., Garavaglia D., Bonazzi C.M., Dell’anna T., Mangioni C., Milani R., Colombo N. Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer. J. Natl. Cancer. Inst. 2011;103:347–351. doi: 10.1093/jnci/djq530.
    1. Boere I.A., van der Burg M.E. Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer. Curr. Pharm. Des. 2012;18:3741–3753. doi: 10.2174/138161212802002634.
    1. Tiersten A.D., Sill M.W., Knight D., Muggia F., Garcia A.A., Swensen R., Warshal D.P., Mannel R.S., Fracasso P.M. A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: A feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: A Gynecologic Oncology Group study. Gynecol. Oncol. 2010;118:303–307. doi: 10.1016/j.ygyno.2010.05.020.
    1. Briasoulis E., Karavasilis V., Tzamakou E., Haidou C., Piperidou C., Pavlidis N. Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: Results of a dose-escalation study. Anticancer Drugs. 2002;13:481–489. doi: 10.1097/00001813-200206000-00006.
    1. Thomas H., Rosenberg P. Role of weekly paclitaxel in the treatment of advanced ovarian cancer. Crit. Rev. Oncol. Hematol. 2002;44:S43–S51. doi: 10.1016/S1040-8428(02)00103-8.
    1. Mori T., Kinoshita Y., Watanabe A., Yamaguchi T., Hosokawa K., Honjo H. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer. Chemother. Pharmacol. 2006;58:665–672. doi: 10.1007/s00280-006-0209-6.
    1. Kumar A., Hoskins P.J., Tinker A.V. Dose-dense paclitaxel in advanced ovarian cancer. Clin. Oncol. (R. Coll. Radiol) 2015;27:40–47. doi: 10.1016/j.clon.2014.10.001.
    1. Kaye S.B. First-line chemotherapy for ovarian cancer—the controversy continues. Br. J. Cancer. 2002;87:813–814. doi: 10.1038/sj.bjc.6600568.
    1. Fiseha T., Mengesha T., Girma R., Kebede E., Gebreweld A. Estimation of renal function in adult outpatients with normal serum creatinine. BMC Res. Notes. 2019;12:462. doi: 10.1186/s13104-019-4487-6.
    1. Chang W.H., Horng H.C., Yeh C.C., Guo C.Y., Chou Y.J., Huang N., Lee W.L., Wang P.H. Risks of female genital tract related cancers (gynecological cancers) or breast cancer in women with and without chronic kidney disease: A population-based cohort study in Taiwan. Medicine. 2018;97:e0157. doi: 10.1097/MD.0000000000010157.
    1. Huang B.S., Chang W.H., Wang K.C., Huang N., Guo C.Y., Chou Y.J., Lee W.L., Wang P.H. Endometriosis might be inversely associated with developing chronic kidney disease: A population-based cohort study in Taiwan. Int. J. Mol. Sci. 2016;17:1079. doi: 10.3390/ijms17071079.
    1. Chung A.E., Shoenbill K., Mitchell S.A., Dueck A.C., Schrag D., Bruner D.W., Minasian L.M., St Germain D., O’Mara A.M., Baumgartner P., et al. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) J. Am. Med. Inform. Assoc. 2019;26:276–285. doi: 10.1093/jamia/ocy169.
    1. Schoen M.W., Basch E., Hudson L.L., Chung A.E., Mendoza T.R., Mitchell S.A., St Germain D., Baumgartner P., Sit L., Rogak L.J., et al. Software for administering the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. JMIR Hum. Factors. 2018;5:e10070. doi: 10.2196/10070.
    1. Raimondi A., Randon G., Sepe P., Claps M., Verzoni E., de Braud F., Procopio G. The evaluation of response to immunotherapy in metastatic renal cell carcinoma: Open challenges in the clinical practice. Int. J. Mol. Sci. 2019;20:4263. doi: 10.3390/ijms20174263.
    1. Seymour L., Bogaerts J., Perrone A., Ford R., Schwartz L.H., Mandrekar S., Lin N.U., Litière S., Dancey J., Chen A., et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet. Oncol. 2017;18:e143–e152. doi: 10.1016/S1470-2045(17)30074-8.
    1. Beaumont H., Bertrand A.S., Klifa C., Patriti S., Cippolini S., Lovera C., Iannessi A. Radiology workflow for RECIST assessment in clinical trials: Can we reconcile time-efficiency and quality? Eur. J. Radiol. 2019;118:257–263. doi: 10.1016/j.ejrad.2019.07.030.
    1. Cheng M., Lee H.H., Chang W.H., Lee N.R., Huang H.Y., Chen Y.J., Horng H.C., Lee W.L., Wang P.H. Weekly dose-dense paclitaxel and triweekly low-dose cisplatin: A well-tolerated and effective chemotherapeutic regimen for first-line treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer. Int. J. Environ. Res. Public Health. 2019;16:4794. doi: 10.3390/ijerph16234794.
    1. Yang Z.J., Zhao B.B., Li L. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer. J. Ovarian. Res. 2016;9:57. doi: 10.1186/s13048-016-0266-3.
    1. Abaid L.N., Micha J.P., Rettenmaier M.A., Brown J.V., Mendivil A.A., Lopez K.L., Goldstein B.H. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma. Cancer. Chemother. Pharmacol. 2013;72:101–107. doi: 10.1007/s00280-013-2173-2.
    1. Fleming N.D., Coleman R.L., Tung C., Westin S.N., Hu W., Sun Y., Bhosale P., Munsell M.F., Sood A.K. Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol. Oncol. 2017;147:41–46. doi: 10.1016/j.ygyno.2017.07.137.
    1. Bun S., Yunokawa M., Ebata T., Shimomura A., Shimoi T., Kodaira M., Yonemori K., Shimizu C., Fujiwara Y., Kato T., et al. Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer. Cancer. Chemother. Pharmacol. 2016;78:745–752. doi: 10.1007/s00280-016-3100-0.
    1. Bun S., Yunokawa M., Ebata T., Kobayashi Kato M., Shimoi T., Kato T., Tamura K. Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: A retrospective study. Int. J. Clin. Oncol. 2019;24:1111–1118. doi: 10.1007/s10147-019-01449-3.
    1. Minagawa Y., Kigawa J., Kanamori Y., Itamochi H., Terakawa N., Okada M., Kitada F. Feasibility study comparing docetaxel–cisplatin versus docetaxel–carboplatin as first-line chemotherapy for ovarian cancer. Gynecol. Oncol. 2006;101:495–498. doi: 10.1016/j.ygyno.2005.11.020.
    1. Morton J.M., George J.N. Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer. J. Oncol. Pract. 2016;12:523–530. doi: 10.1200/JOP.2016.012096.
    1. Mones J.V., Soff G. Management of thrombocytopenia in cancer patients. Cancer. Treat. Res. 2019;179:139–150.
    1. Al-Samkari H., Connors J.M. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Blood Adv. 2019;3:3770–3779. doi: 10.1182/bloodadvances.2019000369.
    1. Boyd L.R., Muggia F.M. Carboplatin/paclitaxel induction in ovarian cancer: The finer points. Oncol. (Williston Park) 2018;32:418–420.
    1. Egorin M.J., Van Echo D.A., Tipping S.J., Olman E.A., Whitacre M.Y., Thompson B.W., Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer. Res. 1984;44:5432–5438.
    1. Wang P.H., Yuan C.C., Shyong W.Y., Chiang S.C., Chao J.Y., Yen M.S., Ng H.T. Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma. Zhonghua Yi Xue Za Zhi (Taipei) 2000;63:220–225.
    1. Elattar A., Bryant A., Winter-Roach B.A., Hatem M., Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst. Rev. 2011:CD007565. doi: 10.1002/14651858.CD007565.pub2.
    1. Javellana M., Hoppenot C., Lengyel E. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecol. Oncol. 2019;152:228–234. doi: 10.1016/j.ygyno.2018.11.007.
    1. Manning-Geist B.L., Hicks-Courant K., Gockley A.A., Clark R.M., Del Carmen M.G., Growdon W.B., Horowitz N.S., Berkowitz R.S., Muto M.G., Worley M.J., Jr. Moving beyond “complete surgical resection” and “optimal”: Is low-volume residual disease another option for primary debulking surgery? Gynecol. Oncol. 2018;150:233–238. doi: 10.1016/j.ygyno.2018.06.015.
    1. Sioulas V.D., Schiavone M.B., Kadouri D., Zivanovic O., Roche K.L., O’Cearbhaill R., Abu-Rustum N.R., Levine D.A., Sonoda Y., Gardner G.J., et al. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy? Gynecol. Oncol. 2017;145:15–20. doi: 10.1016/j.ygyno.2017.02.023.
    1. Lu J., Jiang Y., Qian M., Lv L., Ying X. The improved effects of a multidisciplinary team on the survival of breast cancer patients: Experiences from China. Int. J. Environ. Res. Public Health. 2020;17:277. doi: 10.3390/ijerph17010277.
    1. Natarajan R., Aljaber D., Au D., Thai C., Sanchez A., Nunez A., Resto C., Chavez T., Jankowska M.M., Benmarhnia T., et al. Environmental exposures during puberty: Window of breast cancer risk and epigenetic damage. Int. J. Environ. Res. Public Health. 2020;17:493. doi: 10.3390/ijerph17020493.
    1. Atlan M., Neman J. Targeted transdermal delivery of curcumin for breast cancer prevention. Int. J. Environ. Res. Public Health. 2019;16:4949. doi: 10.3390/ijerph16244949.
    1. Paulauskiene J., Stelemekas M., Ivanauskiene R., Petkeviciene J. The cost-effectiveness analysis of cervical cancer screening using a systematic invitation system in Lithuania. Int. J. Environ. Res. Public Health. 2019;16:5035. doi: 10.3390/ijerph16245035.
    1. Lipscomb J., Escoffery C., Gillespie T.W., Henley S.J., Smith R.A., Chociemski T., Almon L., Jiang R., Sheng X., Goodman M., et al. Improving screening uptake among breast cancer survivors and their first-degree relatives at elevated risk to breast cancer: Results and implications of a randomized study in the state of Georgia. Int. J. Environ. Res. Public Health. 2020;17:977. doi: 10.3390/ijerph17030977.
    1. Harano K., Terauchi F., Katsumata N., Takahashi F., Yasuda M., Takakura S., Takano M., Yamamoto Y., Sugiyama T. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016) Ann. Oncol. 2014;25:251–257.
    1. Dalton H.J., Yu X., Hu L., Kapp D.S., Benjamin I., Monk B.J., Chan J.K. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer. Gynecol. Oncol. 2012;124:199–204. doi: 10.1016/j.ygyno.2011.09.028.
    1. Seagle B.L., Shahabi S. Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecol. Oncol. 2017;145:9–14. doi: 10.1016/j.ygyno.2017.02.014.
    1. Herzog T.J., Cohn D.E. Dose dense chemotherapy for front-line ovarian cancer treatment: The price is right? Gynecol. Oncol. 2017;145:1–2. doi: 10.1016/j.ygyno.2017.03.001.
    1. Foote J., Secord A.A., Liang M., Cohn D.E., Jewell E., Havrilesky L.J. ASCO value framework highlights the relative value of treatment options in ovarian cancer. J. Oncol. Pract. 2017;13:e1030–e1039. doi: 10.1200/JOP.2017.025106.
    1. Wright J.D., Hou J.Y., Burke W.M., Tergas A.I., Chen L., Hu J.C., Ananth C.V., Neugut A.I., Hershman D.L. Utilization and toxicity of alternative delivery methods of adjuvant chemotherapy for ovarian cancer. Obstet. Gynecol. 2016;127:985–991. doi: 10.1097/AOG.0000000000001436.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다